Candel Secures European Medicines Agency Orphan Drug Status For Brain Tumour Candidate

The European Medicines Agency (EMA) Committee for Orphan Medical Products (COMP) has issued a positive opinion on Candel Therapeutics’ CADL application for orphan drug designation for CAN-2409 for the treatment of glioma.

The EMA orphan drug designation for CAN-2409 follows the U.S. Food and Drug Administration (FDA) fast track designation for lead candidate in combination with valacyclovir ensuring standard of care treatment in newly diagnosed high-grade glioma.

Orphan drug designation in the European Union (EU) is granted by the European Commission based on a positive opinion issued by the EMA COMP.

The company is evaluating the effects of treatment with CAN-2409 in high-grade glioma, non-small cell lung cancer, pancreatic cancer, and prostate cancer in ongoing multiple phase 2 and phase 3 clinical trials.

Paul Peter Tak, MD, PhD, FMedSci, President and CEO of Candel, said, "Glioma, while mercifully rare, is a devastating disease with significant morbidity and mortality. The EMA's orphan drug designation recognizes the high unmet need and the potential of CAN-2409 in this patient population. We look forward to working with the EMA and FDA in an effort to bring our investigational medicine to patients as we initiate our phase 3 clinical trial of CAN-2409 in high-grade glioma this year."

The EMA's orphan drug designation is potentially available to companies developing treatments for life-threatening or chronically debilitating conditions that affect no more than five in 10,000 persons in the EU region.

Price Action : Candel shares are trading around 4 percent higher at $3.64 on Thursday at the time of publication.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechPenny StocksHealth CareGeneralEMA Orphan Drug Status
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!